BSX vs IRTC: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BSX is the larger of the two ($61.83B market cap): the incumbent the market prices for continued execution (13.63x forward earnings, beta 0.58). IRTC is the smaller challenger ($3.18B), actually pricier on forward earnings (61.63x): more room to run, but more to prove. If you believe in growth, IRTC fits: analysts expect its revenue to rise 20% next year, against 0% for BSX. If you believe in paying less for profit, BSX fits: it trades at 13.63x forward earnings, against 61.63x for IRTC.
BSX vs IRTC: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BSX | IRTC | What it tells you |
|---|---|---|---|
| Market cap | $61.83B | $3.18B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.63 | 61.63 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.58 | 1.47 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 5% of range | 11% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.41 | 17.87 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BSX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BSX and IRTC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BSX and IRTC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BSX and IRTC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Boston Scientific Corporation (BSX) do?
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.
What does iRhythm Technologies (IRTC) do?
iRhythm makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. The device replaced the older Holter-monitor workflow (short-window, wired recorders) with a longer, more comfortable, water-resistant patch that is mailed back for algorithmic analysis and a physician report. Zio has become the most widely prescribed ambulatory ECG monitor in the US, and iRhythm is extending the franchise with mobile cardiac telemetry, international expansion, and adjacencies such as sleep apnea and primary-care risk stratification. In October 2026 it completed the acquisition of VitalConnect, a wearable-biosensor company with a 30-day mobile cardiac telemetry platform that can track up to 11 physiological parameters, for $237.5 million in cash plus up to about 423,000 shares.
BSX vs IRTC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BSX drivers: Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion.
- IRTC drivers: Zio volume growth and category leadership; Mobile cardiac telemetry: Zio MCT plus VitalConnect.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The most immediate concern is a run of setbacks in 2026. For IRTC, regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT.
BSX or IRTC: which should you pick?
If the story you believe is BSX's (Farapulse and the Pulsed Field Ablation Wave), BSX is the more direct way to own it; if it is IRTC's (Zio volume growth and category leadership), IRTC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BSX and IRTC guides.
BSX vs IRTC: the full fundamentals
BSX. Boston Scientific's trailing P/E of roughly 18x and forward multiple near 14x are far below the sustained premium the stock carried during its high-growth phase. The compression followed a decline of about 56% over the past year, driven by slowing growth, repeated outlook cuts, the September cybersecurity disruption and a third quarter with revenue growth of about 1.4%. At $42.75 on November 20, 2026 the shares sit near the bottom of a $39.57 to $101.91 52-week range and below the analyst mean target of about $49.60 (28 analysts), so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction.
IRTC. At about $95 on November 20, 2026, IRTC trades at roughly 3.7 times trailing sales and 62 times forward earnings, a lower sales multiple than earlier in the year after a 46% drop in the share price even as revenue kept growing in the mid-teens. GAAP earnings are still negative (no trailing P/E), so the valuation leans on volume growth, margin expansion and the MCT strategy more than current profits. The mean analyst target among 15 tracked by Yahoo was about $153, well above the price, and the board's decision to buy back up to $200 million of stock signals how management views the drop.
Headline figures (approximate, November 2026): BSX shows revenue (ttm) ~$21.1 billion (+1.4% YoY in Q3 2026), revenue (q3 2026) ~$5.14 billion, net income (ttm) ~$3.5 billion (profit margin ~16.6%), adjusted eps (q3 2026) $0.73 vs $0.72 est.; IRTC shows revenue (ttm) ~$854M; 2026 guidance midpoint ~$892.5M, q3 2026 revenue growth ~15% YoY (~$221.6M, slightly below consensus), gross / operating margin (ttm) ~72% / ~4.5%, adjusted ebitda (q3 2026) ~$51M, ~23% margin (record).
The bottom line: BSX vs IRTC
BSX and IRTC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BSX and IRTC exposure against your real portfolio. It is not an investment adviser.
Wondering how BSX or IRTC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Boston Scientific Corporation
Ask Walnut's AI anything about BSX and see how it fits what you own.
FAQ
What is the difference between BSX and IRTC?
+
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. iRhythm makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BSX or IRTC the better stock?
+
Neither is universally better. BSX is the larger incumbent; IRTC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BSX or IRTC?
+
On forward P/E (as of November 2026), BSX trades at 13.63x and IRTC at 61.63x, so BSX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BSX and IRTC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BSX vs IRTC?
+
BSX: The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Third-quarter revenue rose only about 1.4%, net income fell to about $582 million from about $907 million in the second quarter, and analysts now model fourth-quarter EPS about 3% below the prior year and 2027 EPS of about $3.13, slightly below 2026. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026, and the mean target has fallen to about $49.60. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12 billion of debt before the November 2026 senior notes offering ($3.0 billion and EUR 4.25 billion), and integration risk from the company's acquisition strategy each add uncertainty. IRTC: Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. Growth is slowing (about 15% in Q3 2026 after about 20% in Q2), and management warned that VitalConnect integration may keep Zio AT sales soft for a quarter or two; Citi downgraded the stock after the report. Data security became a live issue in 2026: unauthorized individuals accessed and downloaded patient information (names, contact details, insurance numbers, dates of birth) from third-party-hosted business applications between June 3 and June 8, 2026, and iRhythm began notifying affected patients on October 2. The company says it does not expect a material financial impact and saw no effect on its devices or patient safety, but breaches can bring litigation and regulatory scrutiny. The balance sheet carries about $726 million of debt against about $561 million of cash at September 30, 2026, and the $100 million accelerated buyback will draw that cash down further. The company is still loss-making on a GAAP basis and trades at a premium earnings multiple, so any volume slowdown, pricing pressure or launch delay could compress the stock further, as its 46% drop in 2026 shows. Competition from larger, better-capitalized players (Philips, Boston Scientific) adds further risk, and medtech reimbursement and regulatory outcomes are difficult to predict.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BSX or IRTC; figures are approximate and dated (as of November 2026). Verify current data before investing.